Cargando…

Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer

BACKGROUND: Mesenchymal-epithelial transition exon14 (METex14) skipping is one of the therapeutic driver oncogene mutations in non-small cell lung cancer (NSCLC), and can be treated with tepotinib and capmatinib. There is only one report on computed tomography (CT) findings of METex14 skipping-posit...

Descripción completa

Detalles Bibliográficos
Autores principales: Watari, Naokazu, Yamaguchi, Kakuhiro, Terada, Hiroaki, Hamai, Kosuke, Masuda, Ken, Nishimura, Yoshifumi, Sakamoto, Shinjiro, Masuda, Takeshi, Horimasu, Yasushi, Miyamoto, Shintaro, Nakashima, Taku, Iwamoto, Hiroshi, Shoda, Hiroyasu, Ishikawa, Nobuhisa, Fujitaka, Kazunori, Miyazaki, Kozue, Miyata, Yoshihiro, Hamada, Hironobu, Awai, Kazuo, Hattori, Noboru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245203/
https://www.ncbi.nlm.nih.gov/pubmed/35773658
http://dx.doi.org/10.1186/s12890-022-02037-4
_version_ 1784738696796307456
author Watari, Naokazu
Yamaguchi, Kakuhiro
Terada, Hiroaki
Hamai, Kosuke
Masuda, Ken
Nishimura, Yoshifumi
Sakamoto, Shinjiro
Masuda, Takeshi
Horimasu, Yasushi
Miyamoto, Shintaro
Nakashima, Taku
Iwamoto, Hiroshi
Shoda, Hiroyasu
Ishikawa, Nobuhisa
Fujitaka, Kazunori
Miyazaki, Kozue
Miyata, Yoshihiro
Hamada, Hironobu
Awai, Kazuo
Hattori, Noboru
author_facet Watari, Naokazu
Yamaguchi, Kakuhiro
Terada, Hiroaki
Hamai, Kosuke
Masuda, Ken
Nishimura, Yoshifumi
Sakamoto, Shinjiro
Masuda, Takeshi
Horimasu, Yasushi
Miyamoto, Shintaro
Nakashima, Taku
Iwamoto, Hiroshi
Shoda, Hiroyasu
Ishikawa, Nobuhisa
Fujitaka, Kazunori
Miyazaki, Kozue
Miyata, Yoshihiro
Hamada, Hironobu
Awai, Kazuo
Hattori, Noboru
author_sort Watari, Naokazu
collection PubMed
description BACKGROUND: Mesenchymal-epithelial transition exon14 (METex14) skipping is one of the therapeutic driver oncogene mutations in non-small cell lung cancer (NSCLC), and can be treated with tepotinib and capmatinib. There is only one report on computed tomography (CT) findings of METex14 skipping-positive NSCLC, which shows that the primary tumor tends to have a large mass in the upper lobe, and extrathoracic metastases are common. This study examined the CT findings of METex14 skipping-positive NSCLC, focusing on the features of the margins and internal structures. METHODS: We consecutively included patients with METex14 skipping-positive NSCLC who were diagnosed between January 2018 and December 2020 at four independent institutions. We retrospectively reviewed the patient demographics and CT findings for tumor margins (invasion into surrounding tissue, lobulation, pleural indentation, spicula, and ground-glass opacity) and internal structures (air bronchograms, cavitation and internal low-density area). RESULTS: Fifteen patients with METex14 skipping-positive NSCLC were identified. Almost half of the patients were men (7/15; 46.7%), and their median age was 75.0 years. More than half were either current or former smokers (9/15; 60.0%). A vast majority of histological subtypes were adenocarcinoma (10/15; 66.7%), followed by pleomorphic carcinoma (3/15; 20.0%) and squamous cell carcinoma (2/15; 13.3%). With regard to CT findings, most primary tumors presented as masses larger than 30 mm (12/15; 80.0%) and were located in the upper lobes (12/15; 80.0%). Invasion into surrounding tissue and presence of internal low-density areas were observed in 60.0% (9/15) and 66.7% (10/15) of the primary tumors, respectively. Additionally, their frequencies increased to 72.7% (8/11) and 90.9% (10/11) in stage III/IV cases, respectively. In lymph node metastasis, internal low-density areas were observed in 8/10 cases (80.0%). Although these two CT features were rarely observed in distant metastases at diagnosis, they became apparent with progression of the metastatic tumor size. CONCLUSIONS: METex14 skipping-positive NSCLC tumors tend to invade surrounding tissue and possess internal low-density areas. These CT findings might be characteristic of METex14 skipping-positive NSCLC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-022-02037-4.
format Online
Article
Text
id pubmed-9245203
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-92452032022-07-01 Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer Watari, Naokazu Yamaguchi, Kakuhiro Terada, Hiroaki Hamai, Kosuke Masuda, Ken Nishimura, Yoshifumi Sakamoto, Shinjiro Masuda, Takeshi Horimasu, Yasushi Miyamoto, Shintaro Nakashima, Taku Iwamoto, Hiroshi Shoda, Hiroyasu Ishikawa, Nobuhisa Fujitaka, Kazunori Miyazaki, Kozue Miyata, Yoshihiro Hamada, Hironobu Awai, Kazuo Hattori, Noboru BMC Pulm Med Research BACKGROUND: Mesenchymal-epithelial transition exon14 (METex14) skipping is one of the therapeutic driver oncogene mutations in non-small cell lung cancer (NSCLC), and can be treated with tepotinib and capmatinib. There is only one report on computed tomography (CT) findings of METex14 skipping-positive NSCLC, which shows that the primary tumor tends to have a large mass in the upper lobe, and extrathoracic metastases are common. This study examined the CT findings of METex14 skipping-positive NSCLC, focusing on the features of the margins and internal structures. METHODS: We consecutively included patients with METex14 skipping-positive NSCLC who were diagnosed between January 2018 and December 2020 at four independent institutions. We retrospectively reviewed the patient demographics and CT findings for tumor margins (invasion into surrounding tissue, lobulation, pleural indentation, spicula, and ground-glass opacity) and internal structures (air bronchograms, cavitation and internal low-density area). RESULTS: Fifteen patients with METex14 skipping-positive NSCLC were identified. Almost half of the patients were men (7/15; 46.7%), and their median age was 75.0 years. More than half were either current or former smokers (9/15; 60.0%). A vast majority of histological subtypes were adenocarcinoma (10/15; 66.7%), followed by pleomorphic carcinoma (3/15; 20.0%) and squamous cell carcinoma (2/15; 13.3%). With regard to CT findings, most primary tumors presented as masses larger than 30 mm (12/15; 80.0%) and were located in the upper lobes (12/15; 80.0%). Invasion into surrounding tissue and presence of internal low-density areas were observed in 60.0% (9/15) and 66.7% (10/15) of the primary tumors, respectively. Additionally, their frequencies increased to 72.7% (8/11) and 90.9% (10/11) in stage III/IV cases, respectively. In lymph node metastasis, internal low-density areas were observed in 8/10 cases (80.0%). Although these two CT features were rarely observed in distant metastases at diagnosis, they became apparent with progression of the metastatic tumor size. CONCLUSIONS: METex14 skipping-positive NSCLC tumors tend to invade surrounding tissue and possess internal low-density areas. These CT findings might be characteristic of METex14 skipping-positive NSCLC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-022-02037-4. BioMed Central 2022-06-30 /pmc/articles/PMC9245203/ /pubmed/35773658 http://dx.doi.org/10.1186/s12890-022-02037-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Watari, Naokazu
Yamaguchi, Kakuhiro
Terada, Hiroaki
Hamai, Kosuke
Masuda, Ken
Nishimura, Yoshifumi
Sakamoto, Shinjiro
Masuda, Takeshi
Horimasu, Yasushi
Miyamoto, Shintaro
Nakashima, Taku
Iwamoto, Hiroshi
Shoda, Hiroyasu
Ishikawa, Nobuhisa
Fujitaka, Kazunori
Miyazaki, Kozue
Miyata, Yoshihiro
Hamada, Hironobu
Awai, Kazuo
Hattori, Noboru
Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer
title Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer
title_full Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer
title_fullStr Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer
title_full_unstemmed Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer
title_short Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer
title_sort characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245203/
https://www.ncbi.nlm.nih.gov/pubmed/35773658
http://dx.doi.org/10.1186/s12890-022-02037-4
work_keys_str_mv AT watarinaokazu characteristiccomputedtomographyfeaturesinmesenchymalepithelialtransitionexon14skippingpositivenonsmallcelllungcancer
AT yamaguchikakuhiro characteristiccomputedtomographyfeaturesinmesenchymalepithelialtransitionexon14skippingpositivenonsmallcelllungcancer
AT teradahiroaki characteristiccomputedtomographyfeaturesinmesenchymalepithelialtransitionexon14skippingpositivenonsmallcelllungcancer
AT hamaikosuke characteristiccomputedtomographyfeaturesinmesenchymalepithelialtransitionexon14skippingpositivenonsmallcelllungcancer
AT masudaken characteristiccomputedtomographyfeaturesinmesenchymalepithelialtransitionexon14skippingpositivenonsmallcelllungcancer
AT nishimurayoshifumi characteristiccomputedtomographyfeaturesinmesenchymalepithelialtransitionexon14skippingpositivenonsmallcelllungcancer
AT sakamotoshinjiro characteristiccomputedtomographyfeaturesinmesenchymalepithelialtransitionexon14skippingpositivenonsmallcelllungcancer
AT masudatakeshi characteristiccomputedtomographyfeaturesinmesenchymalepithelialtransitionexon14skippingpositivenonsmallcelllungcancer
AT horimasuyasushi characteristiccomputedtomographyfeaturesinmesenchymalepithelialtransitionexon14skippingpositivenonsmallcelllungcancer
AT miyamotoshintaro characteristiccomputedtomographyfeaturesinmesenchymalepithelialtransitionexon14skippingpositivenonsmallcelllungcancer
AT nakashimataku characteristiccomputedtomographyfeaturesinmesenchymalepithelialtransitionexon14skippingpositivenonsmallcelllungcancer
AT iwamotohiroshi characteristiccomputedtomographyfeaturesinmesenchymalepithelialtransitionexon14skippingpositivenonsmallcelllungcancer
AT shodahiroyasu characteristiccomputedtomographyfeaturesinmesenchymalepithelialtransitionexon14skippingpositivenonsmallcelllungcancer
AT ishikawanobuhisa characteristiccomputedtomographyfeaturesinmesenchymalepithelialtransitionexon14skippingpositivenonsmallcelllungcancer
AT fujitakakazunori characteristiccomputedtomographyfeaturesinmesenchymalepithelialtransitionexon14skippingpositivenonsmallcelllungcancer
AT miyazakikozue characteristiccomputedtomographyfeaturesinmesenchymalepithelialtransitionexon14skippingpositivenonsmallcelllungcancer
AT miyatayoshihiro characteristiccomputedtomographyfeaturesinmesenchymalepithelialtransitionexon14skippingpositivenonsmallcelllungcancer
AT hamadahironobu characteristiccomputedtomographyfeaturesinmesenchymalepithelialtransitionexon14skippingpositivenonsmallcelllungcancer
AT awaikazuo characteristiccomputedtomographyfeaturesinmesenchymalepithelialtransitionexon14skippingpositivenonsmallcelllungcancer
AT hattorinoboru characteristiccomputedtomographyfeaturesinmesenchymalepithelialtransitionexon14skippingpositivenonsmallcelllungcancer